<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7506858</journal-id>
<journal-id journal-id-type="pubmed-jr-id">611</journal-id>
<journal-id journal-id-type="nlm-ta">Ann N Y Acad Sci</journal-id>
<journal-id journal-id-type="iso-abbrev">Ann. N. Y. Acad. Sci.</journal-id>
<journal-title-group>
<journal-title>Annals of the New York Academy of Sciences</journal-title>
</journal-title-group>
<issn pub-type="ppub">0077-8923</issn>
<issn pub-type="epub">1749-6632</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26866328</article-id>
<article-id pub-id-type="pmc">4870148</article-id>
<article-id pub-id-type="doi">10.1111/nyas.13001</article-id>
<article-id pub-id-type="manuscript">NIHMS746229</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Recent advances in globin research using genome-wide association studies and gene editing</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Orkin</surname>
<given-names>Stuart H.</given-names>
</name>
<aff id="A1">Dana Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School and Howard Hughes Medical Institute, Boston, Massachusetts</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="FN1">Address for correspondence: Stuart H. Orkin, Dana Farber Cancer Institute, 44 Binney St., Boston, MA 02115. <email>Stuart_Orkin@dfci.harvard.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>21</day>
<month>12</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="epub">
<day>11</day>
<month>2</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>3</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>3</month>
<year>2017</year>
</pub-date>
<volume>1368</volume>
<issue>1</issue>
<fpage>5</fpage>
<lpage>10</lpage>
<!--elocation-id from pubmed: 10.1111/nyas.13001-->
<abstract>
<p id="P1">A long-sought goal in the hemoglobin field has been an improved understanding of the mechanisms that regulate the switch from fetal (HbF) to adult (HbA) hemoglobin during development. With such knowledge, the hope is that strategies for directed reactivation of HbF in adults could be devised as an approach to therapy for the β-hemoglobinopathies thalassemia and sickle cell disease. Recent genome-wide association studies led to identification of three loci (<italic>BCL11A, HBS1L-Myb</italic>, and the β-globin cluster itself) in which natural genetic variation is correlated with different HbF levels in populations. Here, the central role of BCL11A in control of HbF is reviewed from the perspective of how findings may be translated to gene therapy in the not-too-distant future. This summary traces the evolution of recent studies from the initial recognition of <italic>BCL11A</italic> through GWAS to identification of critical sequences in an enhancer required for its erythroid-specific expression, thereby highlighting an Achilles heel for genome editing.</p>
</abstract>
<kwd-group>
<kwd>thalassemia</kwd>
<kwd>BCL11A</kwd>
<kwd>gene editing</kwd>
<kwd>enhancer</kwd>
<kwd>CRISPR</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>